文献速递生殖医学

附加治疗是否服务于不孕患者:体外受精附加项目的伦理与监管

Do à la carte menus serve infertility patients? The ethics and regulation of in vitro fertility add-ons.
PubMed 文献 · Fertil Steril · 2019-11-05

本文讨论体外受精(IVF)附加治疗在常规实践中的监管问题。附加治疗常在未证实提高活产率前即被提供(多数为销售),监管始终极少。作者认为在引入临床前应要求强证据,并需向患者传达相关风险与不确定性。

要点

  • 附加治疗常在未证实提高活产率前即进入常规实践,监管始终极少。
  • 部分附加项目(如早期版本的非整倍体植入前遗传学检测)可能降低活产率。
  • 作者认为附加治疗引入临床前应要求强证据,并需向患者传达风险与不确定性。

核心结论

  • 作者认为附加治疗在引入临床前应要求强证据,同时亟待确定向 prospective 患者传达相关风险与不确定性的方法。

研究设计与样本

  • 本文为伦理与监管论述,未报告系统检索范围或样本量。

主要发现

  • 附加治疗以改善受孕机会为前提提供(多数为销售)给接受体外受精的患者,但其监管始终极少。
  • 附加治疗常在未证实提高活产率前即被引入常规实践。
  • 部分附加项目(包括早期版本的非整倍体植入前遗传学检测)可能降低活产率,使绝望的患者支付更多却恶化受孕机会。
  • 知情同意在原则上是一种解决方案,但实践中 impartial 信息与直接面向消费者的广告之间存在明显张力。

关键数值与推荐

  • 原文未报告具体数值或推荐等级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Add-on treatments are the new black. They are provided (most frequently, sold) to patients undergoing in vitro fertilization on the premise that they will improve the chances of having a baby. However, the regulation of add-ons is consistently minimal, meaning that they are introduced into routine practice before they have been shown to improve the live birth rate. Debate on the adequacy of this light-touch approach rages. Defenders argue that demands for a rigorous approval process are paternalistic, as this would delay access to promising treatments. Critics respond that promising treatments may turn out to have adverse effects on patients and their offspring, contradicting the clinician's responsibility to do no harm. Some add-ons, including earlier versions of preimplantation genetic testing for aneuploidy, might even reduce the live birth rate, raising the prospect of desperate patients paying more to worsen their chances. Informed consent represents a solution in principle, but in practice there is a clear tension between impartial information and direct-to-consumer advertising. Because the effects of a treatment cannot be known until it has been robustly evaluated, we argue that strong evidence should be required before add-ons are introduced to the clinic. In the meantime, there is an imperative to identify methods for communicating the associated risks and uncertainties of add-ons to prospective patients.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Wilkinson J, Malpas P, Hammarberg K, et al. Do à la carte menus serve infertility patients? The ethics and regulation of in vitro fertility add-ons. Fertil Steril. 2019. PMID: 31703942. doi:10.1016/j.fertnstert.2019.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。